RLAY
Income statement / Annual
Last year (2024), Relay Therapeutics, Inc.'s total revenue was $10.01 M,
a decrease of 60.83% from the previous year.
In 2024, Relay Therapeutics, Inc.'s net income was -$337.71 M.
See Relay Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$10.01 M |
$25.55 M |
$1.38 M |
$3.03 M |
$82.65 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$5.27 M
|
$4.13 M
|
$3.93 M
|
$3.55 M
|
$2.85 M
|
$2.15 M
|
| Gross Profit |
$10.01 M
|
$20.28 M
|
-$2.75 M
|
-$896,000.00
|
$79.11 M
|
-$2.85 M
|
-$2.15 M
|
| Gross Profit Ratio |
1
|
0.79
|
-1.99
|
-0.3
|
0.96
|
0
|
0
|
| Research and Development Expenses |
$319.09 M
|
$330.02 M
|
$246.36 M
|
$172.65 M
|
$99.86 M
|
$70.31 M
|
$41.03 M
|
| General & Administrative Expenses |
$76.59 M
|
$74.95 M
|
$65.98 M
|
$57.39 M
|
$38.59 M
|
$13.74 M
|
$8.86 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$76.59 M
|
$74.95 M
|
$65.98 M
|
$57.39 M
|
$38.59 M
|
$13.74 M
|
$8.86 M
|
| Other Expenses |
-$13.21 M
|
$0.00
|
-$20,000.00
|
-$4,000.00
|
-$16,000.00
|
-$58,000.00
|
-$9,000.00
|
| Operating Expenses |
$382.48 M
|
$398.55 M
|
$312.33 M
|
$230.04 M
|
$138.45 M
|
$84.05 M
|
$49.89 M
|
| Cost And Expenses |
$382.48 M
|
$398.55 M
|
$312.33 M
|
$230.04 M
|
$138.45 M
|
$84.05 M
|
$49.89 M
|
| Interest Income |
$34.75 M
|
$31.05 M
|
$8.79 M
|
$830,000.00
|
$3.40 M
|
$8.80 M
|
$1.11 M
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$5.46 M
|
$5.27 M
|
$4.13 M
|
$3.93 M
|
$3.55 M
|
$2.85 M
|
$2.15 M
|
| EBITDA |
-$380.21 M |
-$374.15 M |
-$306.82 M |
-$222.18 M |
-$52.25 M |
-$81.20 M |
-$47.74 M |
| EBITDA Ratio |
-37.99
|
-14.65
|
-233.62
|
-29.49
|
-0.63
|
0
|
0
|
| Operating Income Ratio |
-37.22
|
-14.6
|
-216.71
|
-120.4
|
-0.68
|
0
|
0
|
| Total Other Income/Expenses Net |
$34.76 M
|
$31.03 M
|
$8.77 M
|
$826,000.00
|
$3.38 M
|
$8.74 M
|
$1.10 M
|
| Income Before Tax |
-$337.71 M
|
-$341.97 M
|
-$290.51 M
|
-$363.87 M
|
-$52.41 M
|
-$75.31 M
|
-$48.79 M
|
| Income Before Tax Ratio |
-33.75
|
-13.39
|
-210.36
|
-120.13
|
-0.63
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$36.25 M
|
$132.94 M
|
-$3.40 M
|
-$8.80 M
|
$1.10 M
|
| Net Income |
-$337.71 M
|
-$341.97 M
|
-$254.26 M
|
-$496.81 M
|
-$49.01 M
|
-$66.50 M
|
-$48.79 M
|
| Net Income Ratio |
-33.75
|
-13.39
|
-184.11
|
-164.02
|
-0.59
|
0
|
0
|
| EPS |
-2.36 |
-2.79 |
-2.27 |
-5.22 |
-1.15 |
-15.53 |
-19.63 |
| EPS Diluted |
-2.36 |
-2.79 |
-2.27 |
-5.22 |
-1.15 |
-15.53 |
-19.63 |
| Weighted Average Shares Out |
$142.87 M
|
$122.58 M
|
$112.23 M
|
$95.14 M
|
$42.62 M
|
$4.28 M
|
$2.49 M
|
| Weighted Average Shares Out Diluted |
$142.87 M
|
$122.58 M
|
$112.23 M
|
$95.14 M
|
$42.62 M
|
$4.28 M
|
$2.49 M
|
| Link |
|
|
|
|
|
|
|
